{"id":"efc07a51-6180-4a50-859c-ea3920ee30e8","arxiv_id":"2605.29146","paper_version":2,"verdict":"UNVERDICTED","confidence":"LOW","novelty_score":7.0,"correctness_risk":"high","formal_verification":"none","parameter_count":0,"one_line_summary":"SafeRx-Agent introduces the first fine-grained medication recommendation task at fourth-level ATC codes and a knowledge-grounded multi-agent system that improves prediction accuracy while controlling safety risks on MIMIC datasets.","lead":"SafeRx-Agent is a multi-agent LLM framework that recommends medications at a fine-grained level using patient context, external knowledge, and safety checks for interactions and contraindications. A smart generalist might read it to see how AI can be made more traceable and safer for real medical use cases.","discovery_kind":"new_method","skeptic_critique":{"model":"grok-4.3","headline":"Safety verification's reliability in catching missed risks (and benefit of 4th-level ATC) lacks external validation or false-negative metrics.","rationale":"The reader's weakest assumption directly identifies the unverified safety component that the experimental claim depends on. Because the provided abstract supplies no further implementation or evaluation details, this remains the single most load-bearing gap; no other internal inconsistency is detectable from the given text.","tokens_in":1645,"tokens_out":314,"duration_ms":19941,"concrete_test":"Run the reported SafeRx-Agent outputs on MIMIC-III test visits through an independent rule-based checker (e.g., using DrugBank or Lexicomp interaction tables) and compute the fraction of agent-accepted sets that still contain known major interactions; if >5% remain, the verification step does not reliably control risk.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The central claim requires that the multi-agent safety step (using external clinical knowledge) actually filters unsafe sets without missing real interactions/contraindications while preserving or improving fine-grained accuracy. The abstract provides no description of the verification mechanism, no comparison against a deterministic drug-interaction database, and no safety-specific metrics (e.g., recall of known contraindications). If the LLM-based checker has non-zero false-negative rate on MIMIC cases, the reported accuracy gains could be achieved by unsafe recommendations that were not caught. The fourth-level ATC claim similarly assumes subgroup differences materially affect risk, but no ablation against 3rd-level codes is referenced.","agreement_with_reader":"agree"},"referee_report":{"model":"grok-4.3","summary":"The manuscript introduces SafeRx-Agent, a knowledge-grounded multi-agent framework for medication recommendation. It targets two challenges: limited evidence grounding in traditional methods and lack of safety verification in LLM agents, plus the use of broad medication categories in benchmarks that can overestimate risk. The work defines a new fine-grained task using fourth-level ATC codes, proposes a multi-agent system that incorporates patient context, external clinical knowledge, and safety verification for traceable recommendations, and reports experimental results on MIMIC-III and MIMIC-IV showing improved fine-grained prediction accuracy while controlling drug interactions, contraindications, and medication set size.","tokens_in":1760,"tokens_out":450,"duration_ms":27586,"significance":"If the safety verification step can be shown to reliably filter unsafe recommendations, the framework could meaningfully advance safe and explainable LLM-based clinical decision support. The introduction of a fourth-level ATC benchmark is a constructive step toward more realistic safety evaluation in medication recommendation tasks.","major_comments":[{"comment":"Abstract (and wherever the safety verification module is described): the central claim that SafeRx-Agent 'controls drug interactions, contraindications' depends on the multi-agent safety verification step reliably identifying unsafe sets. No description of the verification mechanism, no false-negative rates on known contraindications from MIMIC cases, and no comparison against a deterministic drug-interaction database are provided; without these, it is impossible to rule out that accuracy gains arise from uncaught unsafe recommendations.","section":"Abstract"},{"comment":"Abstract (experimental results paragraph): the reported accuracy improvements on MIMIC-III/IV are presented without reference to baselines, statistical significance tests, error bars, or ablation on the fourth-level ATC granularity versus third-level codes. This makes it difficult to evaluate whether the fine-grained setting materially reduces risk overestimation as claimed.","section":"Abstract"}],"minor_comments":[{"comment":"The abstract would benefit from a one-sentence overview of the multi-agent roles (e.g., which agent performs safety verification) to orient readers before the results claim.","section":"Abstract"}],"recommendation":"major_revision","confidential_remarks":null},"author_rebuttal":{"model":"grok-4.3","summary":"We thank the referee for the constructive feedback highlighting the need for greater transparency on the safety verification mechanism and clearer experimental reporting. We address each major comment below.","responses":[{"response":"We agree the abstract lacks sufficient detail on the verification mechanism. The full manuscript (Section 3.3) describes the multi-agent safety verification process that cross-checks recommendations against patient context and external clinical knowledge bases. To address the concern directly, we will revise the abstract to briefly outline the verification step and add quantitative evaluations: false-negative rates computed on known contraindications extracted from MIMIC cases, plus a head-to-head comparison against a deterministic database such as DrugBank. These additions will appear in a new experimental subsection.","revision_made":"yes","referee_comment":"[Abstract] Abstract (and wherever the safety verification module is described): the central claim that SafeRx-Agent 'controls drug interactions, contraindications' depends on the multi-agent safety verification step reliably identifying unsafe sets. No description of the verification mechanism, no false-negative rates on known contraindications from MIMIC cases, and no comparison against a deterministic drug-interaction database are provided; without these, it is impossible to rule out that accuracy gains arise from uncaught unsafe recommendations."},{"response":"The full manuscript already reports baseline comparisons, statistical significance tests, error bars, and ablations contrasting fourth-level versus third-level ATC granularity (Section 4.3 and Appendix). We will update the abstract's experimental paragraph to explicitly reference the baselines, note statistical significance, and highlight the granularity ablation results that support reduced risk overestimation. This is a clarification rather than new analysis.","revision_made":"yes","referee_comment":"[Abstract] Abstract (experimental results paragraph): the reported accuracy improvements on MIMIC-III/IV are presented without reference to baselines, statistical significance tests, error bars, or ablation on the fourth-level ATC granularity versus third-level codes. This makes it difficult to evaluate whether the fine-grained setting materially reduces risk overestimation as claimed."}],"tokens_in":1319,"tokens_out":403,"duration_ms":21211,"standing_objections":[]},"desk_editor":{"model":"grok-4.3","letter":"The paper claims to be the first to set up medication recommendation at the fourth level of ATC codes and presents SafeRx-Agent as a multi-agent system that grounds recommendations in clinical knowledge and adds safety verification steps. On MIMIC data it reports better fine-grained accuracy while keeping interactions and set sizes in check.\n\nWhat stands out is the focus on explainability and safety in a domain where mistakes matter. The multi-agent design tries to separate context use from verification, which is a reasonable way to address LLM limitations.\n\nThe main weakness is the absence of any concrete description or metrics for the safety verification. The abstract does not explain how the agents check for contraindications or interactions, nor does it report recall on known unsafe cases or compare against a standard database. Without that, the claim that it controls risks rests on untested assumptions. The benefit of fourth-level codes over broader ones is also asserted without an ablation showing it changes outcomes.\n\nThe citation pattern cannot be judged from the abstract alone, but the novelty claim for the task level seems to stand on its own.\n\nThis paper is for researchers focused on clinical decision support and safe AI in healthcare. A reader looking for new task formulations or multi-agent patterns in medical NLP would get some value if the methods hold up under scrutiny.\n\nIt deserves a serious referee because the problem is practically important and the framework is clearly motivated, even though the evidence presented so far is limited to high-level claims. A review process could require the necessary ablations and validation against deterministic drug databases.","headline":"The paper defines a new fourth-level ATC medication task and a multi-agent safety framework, but the abstract gives no evidence that the safety step actually catches risks.","tokens_in":2264,"tokens_out":386,"would_cite":false,"duration_ms":28797,"reading_group":"maybe","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"grok-4.3","headline":"SafeRx-Agent is a multi-agent framework that generates safe, fine-grained medication recommendations using fourth-level ATC codes.","keywords":["medication recommendation","multi-agent framework","drug safety","ATC codes","explainable AI","MIMIC-III","MIMIC-IV","LLM agents"],"falsifier":"A side-by-side comparison where clinicians review SafeRx-Agent outputs for actual patient visits and identify any missed contraindications or interactions that occurred in reality.","tokens_in":2549,"feed_emoji":"💊","tokens_out":549,"duration_ms":31193,"temperature":0.7,"pith_summary":"Existing medication recommendation methods either rely on limited structured codes or use LLMs without adequate safety verification, and benchmarks use broad categories that can overestimate safety. The paper proposes the first fine-grained setting based on fourth-level ATC codes and introduces SafeRx-Agent to address this. SafeRx-Agent is a knowledge-grounded multi-agent system that leverages patient context, external knowledge, and safety checks to produce traceable recommendations. Experiments on MIMIC-III and MIMIC-IV show gains in accuracy alongside controls on interactions, contraindications, and set size. A reader would care if this leads to more reliable AI tools for prescribing that minimize harm.","feed_headline":"AI multi-agent system recommends meds safely at fine ATC level","feed_subtitle":"SafeRx-Agent uses patient context and safety verification to improve accuracy on MIMIC data while limiting interactions.","key_machinery":"The multi-agent framework with knowledge grounding and safety verification for generating fourth-level ATC medication recommendations.","core_discovery":"The paper claims that SafeRx-Agent improves fine-grained medication prediction accuracy while controlling drug interactions, contraindications, and medication set size by using a knowledge-grounded multi-agent framework with patient context, external clinical knowledge, and safety verification on the MIMIC-III and MIMIC-IV datasets.","pith_inferences":["This method could be adapted to recommend other treatments like procedures or therapies.","Real-world deployment would require integration with live electronic health records beyond MIMIC data.","The focus on fourth-level ATC might encourage development of more detailed drug interaction databases."],"forward_implications":["Improves accuracy in fine-grained medication prediction.","Controls for drug interactions and contraindications.","Produces traceable and explainable medication sets.","Maintains appropriate medication set sizes."],"fun_headline_variants":["SafeRx-Agent improves fine-grained med prediction on MIMIC data","Multi-agent system controls drug risks in recommendations","SafeRx framework uses knowledge for safe medication sets","Agents enhance accuracy while limiting interactions contraindications"],"cache_read_input_tokens":2112,"weakest_assumption_plain":"The multi-agent safety verification reliably identifies unsafe recommendations without missing real risks and that fourth-level ATC granularity meaningfully reduces risk overestimation.","fun_headline_variants_meta":{"raw":{"variants":["SafeRx-Agent improves fine-grained med prediction on MIMIC data","Multi-agent system controls drug risks in recommendations","SafeRx framework uses knowledge for safe medication sets","Agents enhance accuracy while limiting interactions contraindications"]},"model":"grok-4.3","cost_usd":0.007242,"raw_usage":{"total_tokens":3291,"prompt_tokens":573,"num_sources_used":0,"completion_tokens":58,"cost_in_usd_ticks":72424500,"prompt_tokens_details":{"text_tokens":573,"audio_tokens":0,"image_tokens":0,"cached_tokens":256},"completion_tokens_details":{"audio_tokens":0,"reasoning_tokens":2660,"accepted_prediction_tokens":0,"rejected_prediction_tokens":0}},"tokens_in":573,"tokens_out":58,"duration_ms":21490,"temperature":1.0,"reasoning_tokens":2660,"cache_read_input_tokens":256,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-06-29T12:16:06.639969+00:00","model_set":{"reader":"grok-4.3"},"falsifier":"A side-by-side comparison where clinicians review SafeRx-Agent outputs for actual patient visits and identify any missed contraindications or interactions that occurred in reality.","supporting_citations":[],"review_version":1}